Stockscreener 앱 받기
0.4902
1.65%
-0.0082
전일 마감가:
$0.4984
열려 있는:
$0.5
하루 거래량:
150.28K
Relative Volume:
0.94
시가총액:
$19.08M
수익:
$7.88M
순이익/손실:
$-69.20M
주가수익비율:
-0.2679
EPS:
-1.83
순현금흐름:
$-69.73M
1주 성능:
-6.00%
1개월 성능:
-14.00%
6개월 성능:
-32.86%
1년 성능:
-54.19%
1일 변동 폭
$0.486
$0.5195
1주일 범위
$0.486
$0.546
52주 변동 폭
$0.475
$1.56
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
BOLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.4901 | 19.08M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.52 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.91 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.46 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.61 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024 - MSN
Bolt Biotherapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics shifts to Nasdaq Capital Market - Investing.com India
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024 - Marketscreener.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Fmr LLC - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Bolt Biotherapeutics stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.53 - Investing.com India
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesBOLT - The Eastern Progress Online
BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully - Simply Wall St
Bolt Biotherapeutics (BOLT) Stock Surges Amid Biotech Sector Mov - GuruFocus.com
Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B - Endpoints News
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Bolt Biotherapeutics stock hits 52-week low at $0.54 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.54 - Investing.com
HC Wainwright Issues Pessimistic Forecast for BOLT Earnings - Defense World
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look - TipRanks
Bolt Biotherapeutics Reports Q3 2024 Financial Results - TipRanks
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot - Houston Chronicle
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation - Yahoo Finance
BOLTBolt Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - The Manila Times
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - Marketscreener.com
Bolt Biotherapeutics (STU:6LP) Cash Flow from Investing : €52.47 Mil (TTM As of Jun. 2024) - GuruFocus.com
Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
BOLT Stock Surges Over 5% Amidst Biotech Sector's Mixed Performa - GuruFocus.com
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - News & Insights
Bolt Biotherapeutics (BOLT) Stock Surges Amid Broad Biotech Indu - GuruFocus.com
Renaissance Technologies LLC Sells 240,898 Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) - Defense World
Renaissance Technologies LLC Has $208,000 Stock Holdings in Hesai Group (NASDAQ:HSAI) - Defense World
Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 39.1% - Defense World
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.85%
4.93%
자본화:
|
볼륨(24시간):